US 12,600,784 B2Granted

Anti-Clec12A antibodies and uses thereof

AssigneeMillennium Pharmaceuticals, Inc.

InventorTomoki Yoshihara

Life of this patent

Estimating the term…

Abstract

Antibodies, fragments thereof and fusion proteins that specifically bind to Clec12A, are described, as well as methods of making and using such antibodies. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various autoimmune diseases and cancers, including leukemia, lymphoma, or myeloma, including, for example, acute myeloid leukemia.

Claims11

Dependent claims

An anti-Clec12A antibody or antigen-binding fragment thereof comprising:

(a) a heavy chain complementarity determining region (HCDR) 1 comprising an amino acid sequence of GGSISTYY (SEQ ID NO:
19), an HCDR2 comprising an amino acid sequence of IYYSGST (SEQ ID NO:
20), an HCDR3 comprising an amino acid sequence of AREDYYGSGSPFDY (SEQ ID NO:
21);
and
a light chain complementarity determining region (LCDR) 1 comprising an amino acid sequence of QGIRYD (SEQ ID NO:
22), an LCDR2 comprising an amino acid sequence of AAS (SEQ ID NO:23), and an LCDR3 comprising an amino acid sequence of LQDYNFPRT (SEQ ID NO:
24);
or
(b) an HCDR1 comprising an amino acid sequence of GFTFSSYG (SEQ ID NO:
73), an HCDR2 comprising an amino acid sequence of ISYDGSDK (SEQ ID NO:
25), and HCDR3 comprising an amino acid sequence of ARDKGYYFDY (SEQ ID NO:
26);
and
an LCDR1 comprising an amino acid sequence of QSVGNRY (SEQ ID NO:
27), an LCDR2 comprising an amino acid sequence of GAS (SEQ ID NO:
28), an LCDR3 comprising an amino acid sequence of QQDYNLPLT (SEQ ID NO:29);
or
(c) an HCDR1 comprising an amino acid sequence of GFTFSSYG (SEQ ID NO:
73), an HCDR2 comprising an amino acid sequence of ISYDGSDK (SEQ ID NO:
25), an HCDR3 comprising an amino acid sequence of ARDGSRYFDY (SEQ ID NO:
30);
and
an LCDR1 comprising an amino acid sequence of QSVHSKY (SEQ ID NO:
31), an LCDR2 comprising an amino acid sequence of GAS (SEQ ID NO:
28), an LCDR3 comprising an amino acid sequence of QQDYNLPIT (SEQ ID NO:
32);
or
(d) an HCDR1 comprising an amino acid sequence of GGSISSSTYY (SEQ ID NO:
33), an HCDR2 comprising an amino acid sequence of THYRGST (SEQ ID NO:
34), an HCDR3 comprising an amino acid sequence of ARELTGEVFDY (SEQ ID NO:
35);
and
an LCDR1 comprising an amino acid sequence of QSISSY (SEQ ID NO:36), an LCDR2 comprising an amino acid sequence of AAS (SEQ ID NO:
23), an LCDR3 comprising an amino acid sequence of QQSYSTPFT (SEQ ID NO:
37);
or
(e) an HCDR1 comprising an amino acid sequence of GGSISTYY (SEQ ID NO:
19), an HCDR2 comprising an amino acid sequence of IYFSGST (SEQ ID NO:
38), and HCDR3 comprising an amino acid sequence of AREDYYGSGSPFDY (SEQ ID NO:21);
and
an LCDR1 comprising an amino acid sequence of QGIRND (SEQ ID NO:
39), an LCDR2 comprising an amino acid sequence of AAS (SEQ ID NO:
23), an LCDR3 comprising an amino acid sequence of LQDYNYPRT (SEQ ID NO:40);
or
(f) an HCDR1 comprising an amino acid sequence of GGSISTDY (SEQ ID NO:41), an HCDR2 comprising an amino acid sequence of IYFSGST (SEQ ID NO:38), and HCDR3 comprising an amino acid sequence of AREDYYGSGSPFDY (SEQ ID NO:21);
and
an LCDR1 comprising an amino acid sequence of QDIRND (SEQ ID NO:42), an LCDR2 comprising an amino acid sequence of AAS (SEQ ID NO:
23), an LCDR3 comprising an amino acid sequence of LQDYNFPRT (SEQ ID NO:
24);
or
(g) an HCDR1 comprising an amino acid sequence of GFTFSSYG (SEQ ID NO:
73), an HCDR2 comprising an amino acid sequence of ISYDGSDK (SEQ ID NO:25), and HCDR3 comprising an amino acid sequence of ARDGQFYFDY (SEQ ID NO:
43);
and
an LCDR1 comprising an amino acid sequence of QSVTSRY (SEQ ID NO:44), an LCDR2 comprising an amino acid sequence of GAS (SEQ ID NO:28), an LCDR3 comprising an amino acid sequence of QQDYNLPLT (SEQ ID NO:29);
or
(h) an HCDR1 comprising an amino acid sequence of GFTFSNYG (SEQ ID NO:
45), an HCDR2 comprising an amino acid sequence of ISYDGSDK (SEQ ID NO:
25), and HCDR3 comprising an amino acid sequence of ARDSGRYFFDY (SEQ ID NO:46);
and
an LCDR1 comprising an amino acid sequence of QSVSSRS (SEQ ID NO:47), an LCDR2 comprising an amino acid sequence of GPS (SEQ ID NO:
48), an LCDR3 comprising an amino acid sequence of HQDYNLPLT (SEQ ID NO:49);
or
(i) an HCDR1 comprising an amino acid sequence of GFTFSKYG (SEQ ID NO:
50), an HCDR2 comprising an amino acid sequence of IWYDGSIK (SEQ ID NO:
51), and HCDR3 comprising an amino acid sequence of ARGSLWFGEFYFDY (SEQ ID NO:
52);
and
an LCDR1 comprising an amino acid sequence of QGISSA (SEQ ID NO:
53), an LCDR2 comprising an amino acid sequence of DAS (SEQ ID NO:
54), an LCDR3 comprising an amino acid sequence of QQFNNYPRT (SEQ ID NO:
55).

70 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/728,664Filed 25 Apr 2022 · us provisional application
Priority: 26 Apr 2021
Published: US 2023/0111279 A113 Apr 2023
Granted: 14 Apr 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07K 16/2851
Against receptors, cell surface antigens or cell surface determinants: against the lectin superfamily, e.g. CD23, CD72
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61P 35/00
Antineoplastic agents
C07K 2317/21
Characterized by taxonomic origin: from primates, e.g. man

Family

Application63/179,755Us provisional application · filed 26 Apr 2021
US 2023/0111279 A1Pre-grant publication · published 13 Apr 2023
US 12,600,784 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Abstract

An anti-Clec12A antibody or antigen-binding fragment thereof comprising:

(a) a heavy chain complementarity determining region (HCDR) 1 comprising an amino acid sequence of GGSISTYY (SEQ ID NO:
19), an HCDR2 comprising an amino acid sequence of IYYSGST (SEQ ID NO:
20), an HCDR3 comprising an amino acid sequence of AREDYYGSGSPFDY (SEQ ID NO:
21);
and
a light chain complementarity determining region (LCDR) 1 comprising an amino acid sequence of QGIRYD (SEQ ID NO:
22), an LCDR2 comprising an amino acid sequence of AAS (SEQ ID NO:23), and an LCDR3 comprising an amino acid sequence of LQDYNFPRT (SEQ ID NO:
24);
or
(b) an HCDR1 comprising an amino acid sequence of GFTFSSYG (SEQ ID NO:
73), an HCDR2 comprising an amino acid sequence of ISYDGSDK (SEQ ID NO:
25), and HCDR3 comprising an amino acid sequence of ARDKGYYFDY (SEQ ID NO:
26);
and
an LCDR1 comprising an amino acid sequence of QSVGNRY (SEQ ID NO:
27), an LCDR2 comprising an amino acid sequence of GAS (SEQ ID NO:
28), an LCDR3 comprising an amino acid sequence of QQDYNLPLT (SEQ ID NO:29);
or
(c) an HCDR1 comprising an amino acid sequence of GFTFSSYG (SEQ ID NO:
73), an HCDR2 comprising an amino acid sequence of ISYDGSDK (SEQ ID NO:
25), an HCDR3 comprising an amino acid sequence of ARDGSRYFDY (SEQ ID NO:
30);
and
an LCDR1 comprising an amino acid sequence of QSVHSKY (SEQ ID NO:
31), an LCDR2 comprising an amino acid sequence of GAS (SEQ ID NO:
28), an LCDR3 comprising an amino acid sequence of QQDYNLPIT (SEQ ID NO:
32);
or
(d) an HCDR1 comprising an amino acid sequence of GGSISSSTYY (SEQ ID NO:
33), an HCDR2 comprising an amino acid sequence of THYRGST (SEQ ID NO:
34), an HCDR3 comprising an amino acid sequence of ARELTGEVFDY (SEQ ID NO:
35);
and
an LCDR1 comprising an amino acid sequence of QSISSY (SEQ ID NO:36), an LCDR2 comprising an amino acid sequence of AAS (SEQ ID NO:
23), an LCDR3 comprising an amino acid sequence of QQSYSTPFT (SEQ ID NO:
37);
or
(e) an HCDR1 comprising an amino acid sequence of GGSISTYY (SEQ ID NO:
19), an HCDR2 comprising an amino acid sequence of IYFSGST (SEQ ID NO:
38), and HCDR3 comprising an amino acid sequence of AREDYYGSGSPFDY (SEQ ID NO:21);
and
an LCDR1 comprising an amino acid sequence of QGIRND (SEQ ID NO:
39), an LCDR2 comprising an amino acid sequence of AAS (SEQ ID NO:
23), an LCDR3 comprising an amino acid sequence of LQDYNYPRT (SEQ ID NO:40);
or
(f) an HCDR1 comprising an amino acid sequence of GGSISTDY (SEQ ID NO:41), an HCDR2 comprising an amino acid sequence of IYFSGST (SEQ ID NO:38), and HCDR3 comprising an amino acid sequence of AREDYYGSGSPFDY (SEQ ID NO:21);
and
an LCDR1 comprising an amino acid sequence of QDIRND (SEQ ID NO:42), an LCDR2 comprising an amino acid sequence of AAS (SEQ ID NO:
23), an LCDR3 comprising an amino acid sequence of LQDYNFPRT (SEQ ID NO:
24);
or
(g) an HCDR1 comprising an amino acid sequence of GFTFSSYG (SEQ ID NO:
73), an HCDR2 comprising an amino acid sequence of ISYDGSDK (SEQ ID NO:25), and HCDR3 comprising an amino acid sequence of ARDGQFYFDY (SEQ ID NO:
43);
and
an LCDR1 comprising an amino acid sequence of QSVTSRY (SEQ ID NO:44), an LCDR2 comprising an amino acid sequence of GAS (SEQ ID NO:28), an LCDR3 comprising an amino acid sequence of QQDYNLPLT (SEQ ID NO:29);
or
(h) an HCDR1 comprising an amino acid sequence of GFTFSNYG (SEQ ID NO:
45), an HCDR2 comprising an amino acid sequence of ISYDGSDK (SEQ ID NO:
25), and HCDR3 comprising an amino acid sequence of ARDSGRYFFDY (SEQ ID NO:46);
and
an LCDR1 comprising an amino acid sequence of QSVSSRS (SEQ ID NO:47), an LCDR2 comprising an amino acid sequence of GPS (SEQ ID NO:
48), an LCDR3 comprising an amino acid sequence of HQDYNLPLT (SEQ ID NO:49);
or
(i) an HCDR1 comprising an amino acid sequence of GFTFSKYG (SEQ ID NO:
50), an HCDR2 comprising an amino acid sequence of IWYDGSIK (SEQ ID NO:
51), and HCDR3 comprising an amino acid sequence of ARGSLWFGEFYFDY (SEQ ID NO:
52);
and
an LCDR1 comprising an amino acid sequence of QGISSA (SEQ ID NO:
53), an LCDR2 comprising an amino acid sequence of DAS (SEQ ID NO:
54), an LCDR3 comprising an amino acid sequence of QQFNNYPRT (SEQ ID NO:
55).

70 more elements

Facts

Application

17/728,664Filed 25 Apr 2022 · us provisional application

Priority

26 Apr 2021

Published

US 2023/0111279 A113 Apr 2023

Granted

14 Apr 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07K 16/2851
Against receptors, cell surface antigens or cell surface determinants: against the lectin superfamily, e.g. CD23, CD72
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61P 35/00
Antineoplastic agents
C07K 2317/21
Characterized by taxonomic origin: from primates, e.g. man